ACT Signature Webinars

Nonclinical Safety Assessment of Prophylactic and Therapeutic Vaccines 

09-21-2017 10:50 AM

Hosted by the American College of Toxicology, in collaboration with the British Toxicology Society, the Society of Toxicologic Pathology, and the Teratology Society

Speakers: Jayanthi Wolf, PhD, Director, Global Regulatory Affairs, Merck & Co., Inc.; Karissa Adkins, PhD, Scientific Director, Vaccines Lead, Takeda Pharmaceuticals; and David Clarke, PhD, DABT, Senior Director, Pfizer, Inc.

Abstract for Regulatory and Scientific Considerations for the Nonclinical Safety Assessment of Prophylactic and Therapeutic Vaccines Webinar:

The approach for the nonclinical safety assessment of prophylactic vaccines for infectious diseases is well-established, with several regulatory guidelines and numerous examples of toxicology studies available in the literature and product approval packages. In contrast, there are few regulatory guidelines covering the nonclinical safety assessment of therapeutic vaccines and limited examples available in the public domain, although the number of therapeutic vaccines entering development continues to grow; including vaccines for cancer, Alzheimer’s disease, and other chronic conditions.

This session will start by providing an overview of the regulatory guidelines and general approach for the nonclinical safety assessment and toxicology studies designs for prophylactic vaccines. This will be followed by a discussion highlighting the similarities and differences with the approach used for therapeutic vaccines. Case studies will be used to illustrate points for consideration with respect to repeat dose and developmental and reproductive toxicity, and other evaluations that may be necessary based on modality and indication.

View Webinar Recording

Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and cohost societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.


0 Favorited
2 Files
docx file
Vaccine Webinar Q&A.docx   28 KB   1 version
Uploaded - 08-27-2020
pdf file
Vaccine Webinar_Final.pdf   956 KB   1 version
Uploaded - 08-27-2020

Related Entries and Links

No Related Resource entered.